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Abstract
Objective—To estimate the economic burden of vision loss and eye disorders in the United 
States population younger than 40 years in 2012.
Design—Econometric and statistical analysis of survey, commercial claims, and census data.
Participants—The United States population younger than 40 years in 2012.
Methods—We categorized costs based on consensus guidelines. We estimated medical costs 
attributable to diagnosed eye-related disorders, undiagnosed vision loss, and medical vision aids 
using Medical Expenditure Panel Survey and MarketScan data. The prevalence of vision 
impairment and blindness were estimated using National Health and Nutrition Examination 
Survey data. We estimated costs from lost productivity using Survey of Income and Program 
Participation. We estimated costs of informal care, low vision aids, special education, school 
screening, government spending, and transfer payments based on published estimates and federal 
budgets. We estimated quality-adjusted life years (QALYs) lost based on published utility values.
Main Outcome Measures—Costs and QALYs lost in 2012.
Results—The economic burden of vision loss and eye disorders among the United States 
population younger than 40 years was $27.5 billion in 2012 (95% confidence interval, $21.5–
$37.2 billion), including $5.9 billion for children and $21.6 billion for adults 18 to 39 years of age. 
Direct costs were $14.5 billion, including $7.3 billion in medical costs for diagnosed disorders, 
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$4.9 billion in refraction correction, $0.5 billion in medical costs for undiagnosed vision loss, and 
$1.8 billion in other direct costs. Indirect costs were $13 billion, primarily because of $12.2 billion 
in productivity losses. In addition, vision loss cost society 215 000 QALYs.
Conclusions—We found a substantial burden resulting from vision loss and eye disorders in the 
United States population younger than 40 years, a population excluded from previous studies. 
Monetizing quality-of-life losses at $50 000 per QALY would add $10.8 billion in additional 
costs, indicating a total economic burden of $38.2 billion. Relative to previously reported 
estimates for the population 40 years of age and older, more than one third of the total cost of 
vision loss and eye disorders may be incurred by persons younger than 40 years.
Disorders of the eye and resulting vision loss impose a significant burden on the United 
States, both economically and socially. In addition to medical costs, the debilitating nature 
of vision loss results in major indirect and nonmedical costs because of decreased 
productivity, quality of life, and independence among those affected. In recent years, several 
studies have estimated the medical and overall economic costs of vision loss and eye 
disorders, but in the United States, these studies have been restricted to adults 40 years of 
age or older.1–5 Rein et al3 estimated the 2004 annual Unites States economic cost of four 
major age-related eye diseases at $35.4 billion, including $19.1 billion in nonmedical costs. 
Frick et al2 estimated largely complementary costs, including medical costs attributable to 
low vision ($5.5 billion per year) and the value of lost quality of life ($10.5 billion per year) 
in the United States in 2004. A Prevent Blindness America report based on both of these 
studies estimated the total annual cost of vision problems in United States adults at $51.4 
billion per year in 2004.6 To our knowledge, the economic burden among the United States 
population younger than 40 years has not been estimated previously.
In this analysis, we estimated the economic burden of vision loss and eye disorders in the 
United States population younger than 40 years, including children from birth through 17 
years of age and adults 18 through 39 years of age. We followed the consensus guidelines 
for research on the cost of vision loss that were developed under the auspices of the 
Association for Research in Vision and Ophthalmology in 2010.7 These guidelines delineate 
definitions for analysis perspectives and specific cost categories that should be included in 
economic studies of vision loss. We included direct and indirect costs resulting from 
uncorrectable vision loss, refractive errors, and diagnosed disorders of the eye and ocular 
adnexa. We also reported the impact of vision loss on quality-of-life losses and estimated the 
monetized value of this burden.
Methods
We estimated the prevalence of vision loss and the treated prevalence of diagnosed eye and 
vision-related disorders. Costs were estimated for each category listed by consensus 
guidelines. Direct costs include medical care attributable to diagnosed disorders, medical 
vision aids, undiagnosed vision loss, low-vision aids or devices, special education, school 
screening, and federal assistance programs. Indirect costs include productivity losses of 
adults, productivity losses of children’s caregivers, transfer payments (not included in total), 
and deadweight loss from transfer payments. Costs also are reported from the payer’s 
perspective, including government, private insurance, and patient costs. All prices and costs 
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were adjusted to 2012 United States dollars using the Consumer Price Index for nonmedical 
costs and medical components of the Consumer Price Index for medical expenses. United 
States population values are based on the 2010 census.
Prevalence of Vision Loss and Diagnosed Disorders
We estimated the prevalence of vision loss based on autorefractor-corrected visual acuity in 
the better-seeing eye as measured in the National Health and Nutrition Examination Survey 
(NHANES) from 2005 through 2008. Visual acuity thresholds for mild and moderate vision 
impairment and blindness are worse than 20/40, worse than 20/80, and worse than 20/200, 
respectively. Respondents who did not have an acuity test because of self-reported blindness 
were included in the prevalence of blindness. No nationally representative data exist on the 
prevalence of corrected bilateral vision loss among children younger than 12 years. We 
estimated the prevalence of vision loss among this population by adjusting the NHANES 
prevalence for 12 to 17 years using age-specific incidence of severe impairment and 
blindness as identified in United Kingdom surveillance data.8 In the sensitivity analysis, we 
assessed the impact of this assumption for children younger than 12 years by measuring the 
impact of varying the prevalence between 0 and the full rate observed among children 12 to 
17 years of age.
To estimate the treated prevalence of diagnosed eye and vision disorders, we identified 
International Classification of Diseases 9th Revision (ICD-9) diagnosis codes related to eye 
and vision conditions.9 We included a broad range of eye and vision disorders, including 
disorders and diseases of the eye, visual function disorders, conjunctivitis, eye injuries and 
burns, and disorders of ocular adnexa, including the eyelids, the orbit, and the lacrimal 
system. We then estimated the treated prevalence of each code as a primary diagnosis using 
pooled data from the 2003 through 2008 Medical Expenditure Panel (MEPS) conditions file.
Medical and Other Health Costs
We calculated costs attributable to diagnosed eye-related disorders, costs attributable to self-
reported low vision in the absence of a diagnosed eye disorder, and medical vision aid costs, 
including glasses and contact lenses, using 2003 through 2008 MEPS data. To identify 
relative costs of individual eye disorder diagnoses, we analyzed private insurance claims for 
individual ICD-9 codes in MarketScan claims data, which represent a subset of the total 
costs captured in MEPS data.
We estimated the medical costs attributable to diagnosed disorders of the eye and ocular 
adnexa and undiagnosed vision loss econometrically on 2003 through 2008 MEPS pooled 
event file data for persons younger than 40 years. We used a general linear model with γ 
distribution and log link to achieve the best fit.10 Because general linear models are 
multiplicative models, separately estimating costs for individual or groups of conditions may 
lead to double counting of costs when the presence of one condition increases the treatment 
costs of another. We controlled for possible double counting by using a process to adjust 
results such that the model would predict 100% of costs when summing across all possible 
combinations of chronic conditions in MEPS.11 The first part of the 2-part model used a 
logistic equation to estimate the probability of positive medical expenditures. The dependent 
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variable in the second part was total medical expenditures excluding medical vision aid and 
optometrist visit costs, which we estimated separately. The primary independent variables 
were the presence of any eye-related, ocular adnexa, or vision-related ICD-9 diagnosis (eye 
disorders) and self-reported low vision in the absence of a vision diagnosis (undiagnosed 
vision loss). Other independent control variables included sociodemographic indicators and 
the comorbidities diabetes and hypertension. We independently estimated costs based on 
payer: private insurance, public payers (such as Medicaid), and patient out-of-pocket costs.
The MEPS collects self-reported costs for optometry visits and the cost for medical vision 
aids (including glasses and contact lenses) separately from other medical costs. We found 
that only a very small proportion of these costs would be predicted by the presence of a 
diagnosed eye or vision disorder or by self-reported low vision. Therefore, we calculated the 
total cost of optometry visits and medical vision aids for all respondents younger than 40 
years in MEPS regardless of any diagnosis or self-reported low vision. We combined the 
cost of optometry visits with the cost of diagnosed vision disorders and separately reported 
the cost of medical vision aids.
Although overall costs are estimated using MEPS, these data could not provide statistically 
significant estimates of relative costs of individual diagnoses. To estimate these, we analyzed 
the 2008 MarketScan Commercial Claims and Encounters Database to estimate the annual 
cost of outpatient claims directly related to each eye disorder diagnosis code. MarketScan 
data are not nationally representative and do not include claims filed under most vision 
plans, which may include ophthalmologic services and most optometry and refractive error-
related costs, but can provide an accurate measure of private insurance claims for individual 
medical diagnoses. We multiplied the average per-person, per–ICD-9 cost for each age 
group by the prevalence of this diagnosis identified in MEPS data and reported the 
proportion of medical costs filed under each diagnosed condition.
Low-Vision Aids and Devices
Low-vision aids include personal, home, and work devices adapted for use by persons with 
low vision. We estimated United States—specific low-vision aid device use for children and 
young adults with vision loss based on the prevalence of vision loss and incremental rates of 
demand identified in France; to our knowledge, these data are not available elsewhere.12 We 
then multiplied these use rates by the estimated United States cost of low-vision aids and 
devices.13 We estimated the cost of guide dogs for the blind by allocating a previous 
estimate of the cost of guide dogs for all ages in the United States based on an assumption of 
equal allocation of guide dog placement to the blind across all ages and adjusting costs for 
inflation.14
Caregivers
We estimated the cost of the additional informal care required for children with vision 
impairment and blindness. We applied relative rates of informal care resulting from vision 
loss identified in France to estimates of the time required to care for any children based on 
age as measured in the American Time Use Survey.13 We valued the resulting incremental 
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informal care time based on the United States average wage rate. We did not include any 
costs for long-term care placement resulting from vision loss.
Special Education
The Individuals with Disabilities Education Act requires states to provide free intervention 
and education programs for children with disabilities, including blindness, from birth 
through 21 years of age. We estimated the number of children enrolled in special education 
because of low vision based on the American Printing House for the Blind registry of 
students who receive assistance through the Act to Promote Education of the Blind. We then 
multiplied this value by the incremental cost of special education programs per student cited 
by the act, which was $11,102 in 2012-adjusted costs.15
School Vision Screening
We estimated the cost of child vision screening programs based on a national survey of 
statewide screening programs and an evaluation of 3 statewide screening programs (Naser N, 
Hartmann EE. Comparison of state guidelines and policies for vision screening and eye 
exams: preschool through early childhood. Poster presented at: ARVO Annual Meeting, 
April 27, 2008; Fort Lauderdale, FL).16 We estimated in-school screening costs by 
multiplying the grade-level population of each state for each grade identified as a screening 
target by the estimated per-student screening cost for school-based acuity and stereopsis 
screening. For preschool screening, we assumed screening would target 3-year-olds with 
screening rates and costs based on those achieved in 2 preschool screening programs 
administered by Prevent Blindness America.16
Federal Assistance Programs
We included the budgetary cost of federal programs that provide services for the blind, 
including the American Printing House for the Blind, the National Library Services for the 
Blind, and the Committee for Purchase from People who are Blind or Severely Disabled. We 
allocated the cost of these programs based on the target age of the programs and the 
proportion of blind among persons younger than 40 years.
Transfers, Tax Losses, and Deadweight Loss
We included the budgetary impact and estimated deadweight loss associated with federal 
transfers and tax deduction programs, including Social Security Disability Insurance, 
Supplemental Security Income, and the Supplemental Nutrition Assistance Program. We 
estimated the reduction in federal income tax revenue resulting from the income tax 
deduction for blind individuals based on the employment rates and median household 
earnings of blind individuals 18 to 39 years of age. We also estimated deadweight loss 
associated with federal Social Security Disability Insurance and Supplemental Security 
Income transfer programs by assuming that 38% of transfer payments are lost because of 
allocative inefficiency.17,18
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Productivity Losses
Productivity losses include the value of labor lost because of blindness and moderate vision 
impairment. We identified median household income by self-reported vision function from 
Survey of Income and Program Participation data for persons 18 to 39 years of age. We 
assumed that self-reported difficulty seeing words was analogous to visual impairment and 
that self-reported inability to see words in print or blindness was analogous to blindness. We 
estimated productivity losses by multiplying the number of blind and moderately impaired 
persons 18 to 39 years of age by the average reduction in median income associated with 
persons with moderate impairment or blindness identified in the survey.
Loss of Well-Being
We estimated the impact of low vision on personal well-being based on average utility 
values for normal, impairment, and blind vision reported by 12 published articles. We 
excluded the only study we found estimating utility values of vision loss for children 
because it was based on only 24 children and reported utility loss values far greater than 
were identified by the adult-based estimates.19
We adjusted the utility values based on age-specific background utilities.20 We then 
multiplied the adjusted utility values by the prevalent visually impaired and blind population 
and calculated quality-adjusted life year (QALY) losses based on the reduction from normal 
vision utilities. Because of a lack of data for the younger population, we do not adjust the 
QALYs for excess mortality because of low vision. We estimated the monetary value of loss 
of well-being based on a commonly cited societal valuation of $50 000 per QALY.2,21
Sensitivity Analyses
We conducted sensitivity analyses to investigate the impact of parameter uncertainty on 
overall results. In a 1-way sensitivity analysis, we varied individual major parameters 
between a low to high range based on the 95% confidence interval of the parameter estimate 
when available and a 50% range when a confidence interval was not available. We also 
conducted a probabilistic sensitivity analysis to estimate the 95% confidence interval of total 
costs. In the probabilistic sensitivity analysis, we simultaneously varied all major parameters 
in the analysis based on random draws from each parameter’s respective distribution in a 
Monte Carlo simulation and reported the 2.5 and 97.5 percentile cost observations (the 
credible interval) as the 95% confidence interval.22
Results
Prevalence of Vision Loss and Diagnosed Disorders
Among persons younger than 40 years, the prevalence of best-corrected vision impairment 
and blindness was 1.30% (Table 1). The prevalence of visual impairment was 1.12% for 
mild impairment (<20/40–20/80) and 0.12% for moderate impairment (<20/80–20/200). The 
prevalence of blindness (<20/200) was low: 0.10% among adults 18 to 39 years of age and 
only 0.01% among children. More than 2 million persons younger than 40 years in the 
United States have uncorrectable vision impairment, and another 98 000 are blind.
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Based on self-reported conditions identified in MEPS data, the treated prevalence of 
diagnosed disorders of the eye and ocular adnexa, excluding disorders of refraction and 
accommodation, is 3.2% among people younger than 40 years, corresponding to almost 5.8 
million persons (Table 2). Thus, almost 3 times as many persons younger than 40 years self-
report an eye-related disorder than have uncorrectable vision loss. Children have a higher 
prevalence of diagnosed conditions than adults younger than 40 years, primarily because of 
disorders of the conjunctiva, which are the most prevalent conditions among children. 
Among adults 18 to 39 years of age, the conditions with highest prevalences were injuries 
and disorders of the globe.
Economic Burden of Vision Loss and Disorders
We estimated the total economic burden of eye disorders among persons younger than 40 
years in 2010 to be $27.5 billion per year in 2012 dollars (Table 3). Diagnosed disorders, 
including costs for optometry visits, totalled $7.3 billion. Medical vision aids, including 
glasses and contact lenses, cost $4.9 billion. Medical costs attributable to undiagnosed vision 
loss were $481 million. All other direct costs totalled $1.8 billion, with the largest 
components consisting of the cost of nonmedical aids and devices ($1 billion), followed by 
the cost of special education ($615 million). School screening programs cost approximately 
$92 million, and federal assistance programs added $42 million. Indirect costs, including 
productivity losses ($12.2 billion), informal care for children ($602 million), and deadweight 
loss from transfer payments ($188 million), totalled $13 billion.
Patients and their families bore 70% of the total economic burden of eye disorders and 
vision loss. Patients paid 25% of costs for diagnosed disorders but more than two thirds of 
the cost for medical vision aids. Private insurance, including vision plans, paid $5.1 billion 
in combined medical costs. Government paid $3.4 billion in total costs, including $1.8 
billion in medical costs and $0.8 billion in assistance programs, transfer payments, and 
deadweight loss. Government spending also included $0.7 billion for special education and 
school screening, which was paid primarily through state and local governments.
Costs by Diagnosis and Provider
Table 2 shows the allocation of private medical insurance costs by diagnosis type based on 
MarketScan commercial insurance claims. These costs do not include claims filed to vision 
insurance plans, which may exclude most costs for disorders of refraction and 
accommodation, and thus we excluded this diagnosis. The highest-cost disorders for persons 
younger than 40 years were disorders of the globe (19%), followed by injuries and burns 
(16%), disorders of the conjunctiva (12%), and other eye disorders (12%). Among adults 18 
to 39 years of age, injuries and burns were the most costly conditions, and disorders of 
conjunctiva accounted for only 8% of medical insurance costs. Strabismus accounted for 
13% of costs for children but only 2% of costs among adults 18 to 39 years of age.
Quality of Life
We estimated that vision loss results in quality-of-life losses of 215 000 QALYs per year, 
including 81 000 QALYs among children and 134 000 QALYs among adults younger than 
40 years (Table 4). A benchmark of $50 000 commonly is cited for societal willingness to 
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pay per QALY gained by health care. Based on this benchmark, the total monetary value of 
the loss of well-being from vision impairment and blindness for the population younger than 
40 years was $10.8 billion, including $4.1 billion for children and $6.7 billion among adults 
younger than 40 years.
Sensitivity Analyses
The results of the 1-way sensitivity analysis are shown in Figure 1. This tornado diagram 
shows the range of total economic burden associated with the range of each parameter or 
parameter category. Results were most sensitive to the prevalence of vision impairment and 
blindness, followed by the reduction in productivity associated with self-reported vision loss. 
On the basis of the probabilistic sensitivity analysis, we estimated a 95% confidence interval 
of $21.5 billion to $37.2 billion in total costs.
Discussion
This study provides the first estimate of the economic burden of vision loss and eye 
disorders among children and adults younger than 40 years in the United States. We 
estimated the economic burden of disorders of the eye, disorders of the ocular adnexa, and 
vision loss in this population to be $27.5 billion in 2012 dollars, including $5.3 billion for 
children younger than 18 years and $21.2 billion incurred by adults 18 to 39 years of age. 
Monetizing the cost of quality-of-life losses at $50 000 per QALY increased the total burden 
by $10.8 billion, bringing the total cost of vision loss and eye disorders to $38.2 billion for 
the United States population younger than 40 years, including $10 billion for children and 
$28.2 billion for adults 18 to 39 years of age. Based on this total, among the entire 
population younger than 40 years, the per-person cost of vision loss and eye disorders was 
$230. Diagnosed disorders cost $1370 per each person with a diagnosis. All other costs 
totalled $9400 per person with vision loss, including $40 400 per person blind.
Previous studies estimated the economic and quality-of-life burden of eye disorders and 
vision loss among the United States population 40 years of age or older to be $51.4 billion in 
2004. Updating these costs for general and medical inflation implied a cost of $66.6 billion 
in 2012 dollars. Although methodologic differences complicate direct comparison with this 
study, combining this total with our results yielded a total burden of $104.8 billion in 2012 
dollars for the entire United States population, including $56.8 billion in direct costs and $48 
billion in indirect costs. It is possible that the true total cost is even higher because the 
estimates for the population 40 years of age or older are based on the cost of only 4 eye 
disorders and do not include most costs of refraction correction and because updating these 
costs based on the Consumer Price Index will not account fully for newly available therapies 
and treatments.
At $104 billion, this estimate of the cost of vision loss and eye disorders is among the 
highest estimated costs for health conditions in the United States. A recent report estimated 
the burden of several of the costliest chronic diseases in the United States, but did not 
include eye- and vision-related conditions.23 Although subject to substantial methodological 
differences, our estimate of the direct costs of eye and vision disorders would have placed as 
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the fifth costliest disease. This is in line with findings from Australia, where vision disorders 
are estimated to be the seventh costliest health condition.1
This study was subject to several limitations and assumptions. The prevalence of diagnosed 
disorders was based on self-reported conditions and verified medical encounters in MEPS 
data. Unlike other medical costs, the costs for optometry visits and medical vision aids were 
not verified by MEPS. The allocation of costs by diagnosis group were based on MarketScan 
commercial claims, which is not nationally representative and excludes most claims filed 
under vision insurance plans, out-of-pocket costs, and government insurance payments. The 
prevalence of visual impairment and blindness is based on autorefractor-corrected near 
distance acuity as measured by NHANES from 2005 through 2008. Contrast sensitivity and 
visual field were not assessed among participants younger than 40 years. The NHANES did 
not assess acuity among participants younger than 12 years. We imputed prevalence in this 
age group based on the incidence of blindness reported in the United Kingdom and the 
prevalence among older children in the NHANES data, which may introduce bias. We 
expect that this may have underestimated the prevalence of visual impairment at very young 
ages. The sensitivity analysis identified the prevalence of vision loss as the primary cause of 
uncertainty in results, almost entirely because of its impact on productivity losses. The 
QALY losses similarly are sensitive to the prevalence of vision loss. We found no data on the 
relative demand for assistive living devices or informal care resulting from vision loss for 
persons in the United States. We assumed that the relative impact on demand resulting from 
vision loss in the United States was identical to rates observed in Europe, which might have 
introduced bias. We did not include the cost of vision screening other than school and 
preschool screening, such as acuity chart screening during annual physicals or well-child 
checks. Finally, we did not include the monetized value of quality-of-life losses in our 
primary results because of limitations and uncertainty in the utility loss associated with 
vision loss, the monetary value of a QALY, and controversy over their inclusion in economic 
burden studies.
Not unlike many other chronic conditions, most of the costs of eye and vision problems are 
borne by older adults. However, we found that the burden of disease among the population 
younger than 40 years remained substantial, and many of these costs were the result of 
chronic and persistent conditions that will continue to accrue direct and indirect costs for the 
duration of an individual’s life. Recently published guidelines focused attention on the need 
to account for the many nonmedical and indirect costs of eye and vision problems. Future 
research on the economic burden of eye disorders and vision loss also should consider the 
burden faced by all age groups.
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Figure 1. 
Graph showing the results of the univariate sensitivity analysis. Bars represent the range of 
total burden associated with changes in the respective parameter from minimum to 
maximum values. Costs are shown as billions of dollars. Distributions denoted by CI 
represent 95% confidence intervals; others represent uniform distributions within the range 
50% to 150% of the baseline estimate.
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Table 4
Quality-of-Life Losses
Quality-of-Life
Measure
0–17 Years
of Age
18–39 Years
of Age
Total Younger
than 40 Years
QALY losses
  Visual impairment 79 799 110 534 190 333
  Blindness 1663 23 177 24 840
  Total QALYs lost 81 462 133 711 215 173
Monetary value of
  quality-of-life losses
  $50 000 per QALY* $4073 $6686 $10 759
QALY = quality-adjusted life year.
Units of measure for the first 3 rows are QALYs.
*
Monetary costs are in millions.
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